{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:50Z","timestamp":1785514070271,"version":"3.56.0"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.1248\/bpb.b23-00487","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T22:26:00Z","timestamp":1701383160000},"page":"1826-1831","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets"],"prefix":"10.1248","volume":"46","author":[{"given":"Masami","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Osaka-fu, Saiseikai Noe Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Jimaru","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Osaka-fu, Saiseikai Noe Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Torii","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Osaka-fu, Saiseikai Noe Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mitsuba","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Osaka-fu, Saiseikai Noe Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Osaka-fu, Saiseikai Noe Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) The British Pain Society, Opioids for persistent pain: summary of guidance on good practice from the British Pain Society. <i>Br. J. Pain.<\/i>, <b>6<\/b>, 9\u201310 (2012).","DOI":"10.1177\/2049463712436536"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Plante GE, VanItallie TB. Opioids for cancer pain: the challenge of optimizing treatment. <i>Metabolism<\/i>, <b>59<\/b> (Suppl. 1), S47\u2013S52 (2010).","DOI":"10.1016\/j.metabol.2010.07.010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lazzari M, Greco MT, Marcassa C, Finocchi S, Caldarulo C, Corli O. Efficacy and tolerability of oral oxycodone and oxycodone\/naloxone combination in opioid-na\u00efve cancer patients: a propensity analysis. <i>Drug Des. Devel. Ther.<\/i>, <b>9<\/b>, 5863\u20135872 (2015).","DOI":"10.2147\/DDDT.S92998"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Evolving paradigms in the treatment of opioid induced bowel dysfunction. <i>Therap. Adv. Gastroenterol.<\/i>, <b>8<\/b>, 360\u2013372 (2015).","DOI":"10.1177\/1756283X15589526"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone\/naloxone. <i>Clin. Drug Investig.<\/i>, <b>35<\/b>, 1\u201311 (2015).","DOI":"10.1007\/s40261-014-0254-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. <i>Am. J. Gastroenterol.<\/i>, <b>106<\/b>, 835\u2013842, quiz, 843 (2011).","DOI":"10.1038\/ajg.2011.30"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bruner HC, Atayee RS, Edmonds KP, Buckholz GT. Clinical utility of naloxegol in the treatment of opioid-induced constipation. <i>J. Pain Res.<\/i>, <b>8<\/b>, 289\u2013294 (2015).","DOI":"10.2147\/JPR.S61326"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hayashi S, Suda N, Kawakubo T, Shimoyama N. The suppression effect of the opioid receptor antagonist, naldemedine for opioid-induced constipation and nausea\/vomiting. <i>Iryou Yakugaku (Jpn. J. Pharm. Health Care Sci.)<\/i>, <b>45<\/b>, 667\u2013673 (2019).","DOI":"10.5649\/jjphcs.45.667"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. <i>Expert Opin. Investig. Drugs<\/i>, <b>20<\/b>, 1047\u20131056 (2011).","DOI":"10.1517\/13543784.2011.592830"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mallick-Searle T, Fillman M. The pathophysiology, incidence, impact, and treatment of opioid-induced nausea and vomiting. <i>J. Am. Assoc. Nurse Pract.<\/i>, <b>29<\/b>, 704\u2013710 (2017).","DOI":"10.1002\/2327-6924.12532"},{"key":"11","unstructured":"11) Japanese Society for Palliative medicine. <i>Clinical Guidelines for Cancer Pain Management.<\/i> 3rd Ed., Kanehara &amp; Co., Ltd., Tokyo Japan (2020)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shirata C, Shida T, Hatakeyama T, Ogura J, Yamakawa M, Suzuki N, Yamaguchi H. Effect of the opioid administration period before the initiation of naldemedine administration on the prevalence of diarrhea. <i>Iryo Yakugaku (Jpn. J. Pharm. Health Care Sci.)<\/i>, <b>47<\/b>, 411\u2013417 (2021).","DOI":"10.5649\/jjphcs.47.411"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hashizume J, Shiojiri K, Ryu E, Kawauchi Y, Hasegawa K, Ezaki N, Yamashita H, Ishii K, Harasawa H, Nakamura T, Sasaki H, Kodama Y. Analysis of predictive factors for diarrhea after the administration of naldemedine. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 1081\u20131087 (2021).","DOI":"10.1248\/bpb.b21-00209"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Takagi Y, Osawa G, Kato Y, Ikezawa E, Kobayashi C, Aruga E. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study. <i>BMC Gastroenterol.<\/i>, <b>20<\/b>, 25 (2020).","DOI":"10.1186\/s12876-020-1173-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yamada M, Matsumura C, Jimaru Y, Ueno R, Takahashi K, Yano Y. Effect of continuous pharmacist interventions on pain control and side effect management in outpatients with cancer receiving opioid treatments. <i>Biol. Pharm. Bull.<\/i>, <b>41<\/b>, 858\u2013863 (2018).","DOI":"10.1248\/bpb.b17-00749"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Miyashita M, Matoba K, Sasahara T, Kizawa Y, Maruguchi M, Abe M, Kawa M, Shima Y. Reliability and validity of the Japanese version of the Support Team Assessment Schedule (STAS-J). <i>Palliat. Support. Care<\/i>, <b>2<\/b>, 379\u2013385 (2004).","DOI":"10.1017\/S1478951504040507"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. <i>Scand. J. Gastroenterol.<\/i>, <b>32<\/b>, 920\u2013924 (1997).","DOI":"10.3109\/00365529709011203"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. <i>Bone Marrow Transplant.<\/i>, <b>48<\/b>, 452\u2013458 (2013).","DOI":"10.1038\/bmt.2012.244"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kato S, Saito Y, Onoda H, Kumai M, Imai S, Tsuruga K, Takekuma Y, Sugawara M. Efficacy Survey of Naldemedine in the Poor-performance Status Group. <i>Yakugaku Zasshi<\/i>, <b>142<\/b>, 755\u2013760 (2022).","DOI":"10.1248\/yakushi.22-00005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sada H, Kajizono M, Ushio S, Esumi S, Kitamura Y, Sendo T. The efficacy and safety of lubiprostone for constipation in cancer patients compared with non-cancer patients: a retrospective cohort study. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1699\u20131706 (2020).","DOI":"10.1248\/bpb.b20-00398"},{"key":"21","unstructured":"21) Shionogi &amp; Co., Ltd., Symproic\u00ae Tablets 0.2\u2009mg, Interview form, Revised in May 2021 (5th ed.)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. <i>Cochrane Database Syst. Rev.<\/i>, <b>6<\/b>, CD006332 (2022).","DOI":"10.1136\/spcare-2021-MCRC.6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ozaki A, Kessoku T, Tanaka K, <i>et al.<\/i> Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. <i>Cancers<\/i> (Basel), <b>14<\/b>, 2112 (2022).","DOI":"10.3390\/cancers14092112"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/12\/46_b23-00487\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:30:59Z","timestamp":1701487859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/12\/46_b23-00487\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00487","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"b23-00487"}}